CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

liraglutide

Last Updated: December 24, 2020
Result type: Reports
Project Number: SR0668-000
Product Line: Reimbursement Review

Generic Name: liraglutide

Brand Name: Saxenda

Manufacturer: Novo Nordisk Canada Inc.

Therapeutic Area: Chronic weight management in adults

Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

Manufacturer Requested Reimbursement Criteria1: An adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients who have been diagnosed with: Obesity (BMI 30 kg/m2) AND prediabetes, or Overweight (BMI 27 kg/m2 and 30 kg/m2) with one or more weight-related comorbidity AND prediabetes.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 26, 2020
Call for patient/clinician input closedJanuary 22, 2021
Submission receivedDecember 23, 2020
Submission acceptedJanuary 14, 2021
Review initiatedJanuary 15, 2021
Draft CADTH review report(s) provided to sponsor for commentMarch 31, 2021
Deadline for sponsors commentsApril 12, 2021
CADTH responses on draft review report(s) provided to sponsorMay 07, 2021
Expert committee meeting (initial)May 19, 2021
Draft recommendation issued to sponsorJune 01, 2021
To
June 03, 2021
Draft recommendation posted for stakeholder feedback-